Strategies to improve control of blood pressure in hypertension: moving towards a 70% objective

References

• Bramlage P, Böhm M, Volpe M et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J. Clin. Hypertens. (Greenwich) 12(9), 666–677 (2010).
   PubMed Web of Science ®Google Scholar
• Ignatius J. ‘RR 160/80’ Scipione Riva-Rocci (1863–1937). Duodecim 109(17), 1493–1494 (1993).
   PubMedGoogle Scholar
• Prugger C, Keil U, Wellmann J et al.; EUROASPIRE III Study Group. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. J. Hypertens. 29(8), 1641–1648 (2011).
   PubMedGoogle Scholar
• Chobanian AV. Shattuck lecture. The hypertension paradox – more uncontrolled disease despite improved therapy. N. Engl. J. Med. 361(9), 878–887 (2009).
   PubMed Web of Science ®Google Scholar
• Volpe M, Tocci G, Trimarco B et al. Blood pressure control in Italy: results of recent surveys on hypertension. J. Hypertens. 25(7), 1491–1498 (2007).
   PubMed Web of Science ®Google Scholar
• Hartmann B, Weise H, Bassenge E. Quality assurance in Riva–Rocci blood pressure measurement: simultaneous sphygmomanometry with open and covered pressure display. Z. Kardiol. 77(8), 537–542 (1988).
   PubMedGoogle Scholar
• Mancia G, De Backer G, Dominiczak A et al.; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J. Hypertens. 25(9), 1751–1762 (2007).
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23), 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever PS, Poulter NR et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489), 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359(23), 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Cushman WC, Davis BR, Pressel SL et al.; ALLHAT Collaborative Research Group. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J. Clin. Hypertens. (Greenwich) 14(1), 20–31 (2012).
   PubMed Web of Science ®Google Scholar
• Lorenz R. Automatic Blood pressure determination according to the Riva–Rocci–Korotkov technic. Dtsch. Med. Wochenschr. 93(14), 690–694 (1968).
   PubMedGoogle Scholar
• Mourad JJ, Girerd X. Objective for 2015: 70% of treated and controlled hypertensive patients. Seven key points to reach this goal in practice. A joint call for action of the French League Against Hypertension and the French Society of Hypertension. J. Mal. Vasc. 37(6), 295–299 (2012).
   PubMedGoogle Scholar
• Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 303(20), 2043–2050 (2010).
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S et al.; Losartan Intervention for Endpoint reduction in hypertension Study Investigations. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) study. Circulation 108(6), 684–690 (2003).
   PubMed Web of Science ®Google Scholar
• Volpe M, Tocci G. Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice. Expert Rev. Cardiovasc. Ther. 8(6), 811–820 (2010).
   PubMedGoogle Scholar
• Volpe M, Tocci G. Managing hypertension in cardiology practice according to risk profile. Int. J. Clin. Pract. 62(9), 1403–1412 (2008).
   PubMedGoogle Scholar
• Volpe M, Tocci G. Global cardiovascular risk management in primary prevention. Curr. Vasc. Pharmacol. 10(6), 709–711 (2012).
   PubMedGoogle Scholar
• Mancia G, Laurent S, Agabiti-Rosei E et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27(11), 2121–2158 (2009).
   PubMed Web of Science ®Google Scholar
• Corrao G, Parodi A, Zambon A et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J. Hypertens. 28(7), 1584–1590 (2010).
   PubMed Web of Science ®Google Scholar
• Corrao G, Zambon A, Parodi A et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J. Hypertens. 26(4), 819–824 (2008).
   PubMed Web of Science ®Google Scholar
• Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 122(3), 290–300 (2009).
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326(7404), 1427 (2003).
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 18(6), 308–347 (2009).
   PubMed Web of Science ®Google Scholar
• Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin. Ther. 32(7), 1252–1269 (2010).
   PubMed Web of Science ®Google Scholar
• Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin. Drug Investig. 32(10), 649–664 (2012).
   PubMed Web of Science ®Google Scholar
• Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376(9756), 1903–1909 (2010).
   PubMed Web of Science ®Google Scholar
• Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57(5), 911–917 (2011).
   PubMed Web of Science ®Google Scholar
• Volpe M, Rosei EA, Ambrosioni E et al. Renal artery denervation for treating resistant hypertension: definition of the disease, patient selection and description of the procedure. High Blood Press. Cardiovasc. Prev. 19(4), 237–244 (2012).
   PubMedGoogle Scholar
• Anschutz F, Burkert E. The errors in auscultatory measurement of the blood pressure according to Riva–Rocci–Korotkoff on extensive soft parts. Z. Kreislaufforsch. 43(9–10), 335–343 (1954).
   PubMedGoogle Scholar
• Parving HH, Brenner BM, McMurray JJ et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. 24(5), 1663–1671 (2009).
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557), 201–207 (2007).
   PubMed Web of Science ®Google Scholar
• Cicala S, Devereux RB, de Simone G et al. Electrocardiographic and echocardiographic detection of myocardial infarction in patients with left-ventricular hypertrophy. The LIFE Study. Am. J. Hypertens. 20(7), 771–776 (2007).
   PubMed Web of Science ®Google Scholar
• Palmieri V, Okin PM, Bella JN et al. Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study. J. Hypertens. 24(10), 2079–2084 (2006).
   PubMedGoogle Scholar
• Owada A, Suda S, Hata T, Miyake S. The effects of bisoprolol, a selective β1-blocker, on glucose metabolism by long-term administration in essential hypertension. Clin. Exp. Hypertens. 23(4), 305–316 (2001).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55(2), 399–407 (2010).
   PubMed Web of Science ®Google Scholar